Restoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative Medicine

Policy perspective on FDA regulation of ALS and regenerative medicine therapies, arguing for consistent evidentiary standards in rare and fatal disease.